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Abstract
Background Regional citrate anticoagulation (RCA) is one of
the methods used to prevent clotting in continuous renal
replacement therapy (CRRT). The aim of this study was to
describe the outcomes and complications of RCA-CRRT in
comparison to heparin anticoagulation (HA)-CRRT in criti-
cally ill children.
Methods This study was a retrospective review of 30 critically
ill children (16 on RCA- and 14 on HA-CRRT) who
underwent at least 24 h of CRRT. The mean body weight of
the children was 8.69±5.63 kg. RCA-CRRT was performed
with a commercially available pre-dilution citrate solution
(Prismocitrate 18/0).
Results The mean time on RCA-CRRT and HA-CRRT was
148.73±131.58 and 110.24±105.38 h, respectively. Circuit
lifetime was significantly higher in RCA-CRRT than in HA-
CRRT (58.04±51.18 h vs. 37.64±32.51 h, respectively; p =
0.030). Circuit clotting was observed in 11.63 % of children
receiving RCA-CRRT and 34.15 % of those receiving HA-
CRRT. Episodic electrolyte and metabolic disturbances were
more common in children receiving RCA-CRRT. The surviv-
al at discharge from the hospital was 37.5 and 14.3 % among
children receiving RCA-CRRT and HA-CRRT, respectively.
Conclusions In critically ill children with a low body weight,
RCA appeared to be safe and easy to used. Among our patient
cohort, RCAwas more effective in preventing circuit clotting
and provided a better circuit lifetime than HA.
Keywords Anticoagulation . Citrate . Children . Renal
replacement therapy
Introduction
Continuous forms of renal replacement therapy (CRRT) have
become established as the treatment of choice for supporting
critically ill patients with acute kidney injury [1, 2]. These
patients present with activation of the coagulation cascade,
peripheral mononuclear cells and platelets, as well as a reduc-
tion in natural anticoagulants; consequently, they are
prothrombotic [3]. Regional anticoagulation with citrate
(RCA) is one method used for preventing clotting in the CRRT
circuit. The advantages of RCA include a better circuit lifetime
as compared to unfractionated heparin anticoagulation (HA)
and reduction of heparin-induced thrombocytopenia. The latter
is of particular relevance in patients with a high risk of bleeding.
A number of studies have reported that HA-CRRT is associated
with a reduction of bleeding due to regional anticoagulation,
which applies only to the circuit, and a lack of systemic
anticoagulation [3–6]. In contrast, a recent meta-analysis of
488 patients did not show any difference between heparin and
citrate in terms of circuit life with the main difference between
the two modalities being a decrease in bleeding complications
with citrate [7]. However, there was a significant heterogeneity
in the primary outcome of the studied group. Citrate can pro-
vide anticoagulation of blood since it binds with calcium and
renders calcium unavailable to the clotting cascade. The ab-
sence of calcium prevents clotting. Nevertheless, excess citrate
may lead to metabolic complications (acidosis or alkalosis) and
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electrolyte disturbances, especially hyper- and hyponatremia,
and hyper- and hypocalcemia [3–5].
Only a few studies have reported RCA-CRRT use and
outcomes in children. The aim of this study was, therefore, to
describe the clinical application, outcome and complications of
RCA-CRRT in comparison to HA-CRRT in critically ill children.
Methods
A retrospective review was conducted in 30 children (mean
body weight 8.69±5.63 kg) who had received at least 24 h of
continuous arterio–venous or venous–venous hemodiafiltration
in the University Hospital, Poznan, Poland, between January
and December 2012. HA was used as the standard
anticoagulation method (n =14) at the University Hospital until
the middle of 2012 when it was replaced by RCA which was
used thereafter in the treatment of new patients (n =16). No
special selection or randomization was used. Disease categories
in these children included nephrotic syndrome (2 patients),
multiorgan dysfunction due to cardiac surgery (18 children),
sepsis (3 children), leukemia (3 children) and metabolic dis-
eases (2 children). CRRTwas started due to clinical features and
the presence of life-threatening edemas despite enhanced diure-
sis. Therefore, in some cases, CRRF was started before the
failure stage according to pediatric RIFLE (Risk, Injury, Fail-
ure, Loss, End-stage kidney disease) criteria [8]. Children on
RCA-CRRT did not differ from those on HA-CRRT in terms of
age, body weight and creatinine level. Initial clinical and labo-
ratory data are given in Table 1.
Ethics Committee approval was not required for this ob-
servational study because all data reported, as well as
anticoagulation method assignment, are part of our routine
medical procedures and guidelines.
CRRT was performed using the Prismaflex system
(Gambro, Lundia AB, Lund, Sweden) including the
Prismaflex HF-20 or —60 hemofiltration system (Gambro).
Vascular access varied based on the size of the child. In
neonates weighing <5 kg, two central catheters were used with
minimum size of 20G for arterial access and 18G for venous
access. In older children double-lumen accesses were used.
RCA-CRRT was performed using a commercially avail-
able pre-dilution citrate solution (Prismocitrate 18/0; Gambro)
and a commercially available dialysate normocarbonate solu-
tion (Prism0cal B22; Gambro), according to the Intensive
Care Units Therapeutic Recommendation for CRRT by
Gambro, which is based on the recommendations of Tolwani
et al. [9]. Prismocitrate 18/0 consists of 0.5 % trisodium citrate
solution, which contains 18 mmol/l citrate without citric acid
and 140 mmol/l sodium. In relation to blood flow rate, the
citrate solution rate was set to achieve a circuit citrate concen-
tration of 3 mmol/l blood flow. The dosage of citrate in
millimoles per liter blood flow was defined as the pre-
dilution citrate load. The pre-dilution citrate load was
Table 1 Clinical characteristics







ous renal replacement therapy;
CS, after cardiac surgery; S, sep-
sis; NS, nephrotic syndrome;
LEU, leukemia; na, non-
applicable
Unless indicated otherwise, data
are presented as the mean ± stan-
dard deviation (SD)
Clinical characteristics RCA-CRRT HA-CRRT p
No. of patients 16 14 na
Gender (n) 7 females/9 males 8f/6m na
Disease categories (n) CS (11)/S (3)/NS (2) CS (7)/LEU (3)/MODS (2) na
Age (months) 15.25±24.10 24.15±27.96 0.523
Weight (kg) 7.76±4.67 9.77±6.21 0.355
Mean arterial pressure (mmHg) 72±27.59 66±12.86 0.938
Edema (%) 100 85 na
Mechanical ventilation (%) 75 86 na
Total parenteral nutrition (%) 75 93 na
Multiorgan dysfunction syndrome (MODS) (%) 75 93 na
Creatinine (mg/dl) 1.04±0.66 0.93±0.79 0.294
Blood urea nitrogen (mg/dl) 103.56±70.61 96.64±62.72 0.822
Aspartate aminotransferase (IU/l) 1828.67±3230.12 592.64±1096.29 0.354
Acute liver failure (n) 8 (50 %) 6 (43 %) na
Systemic sodium (mmol/l) 144.82±8.67 142.06±8.89 0.377
Systemic ionized Ca (mmol/l) 1.11±0.18 1.10±0.17 0.892
Systemic lactate (mmol/l) 6.44±4.82 5.15±5.35 0.492
pH (units) 7.39±0.13 7.41±0.08 0.983
HCO3 (mmol/l) 21.46±5.54 25.02±6.14 0.387
Base excess (units) −3.68±6.85 0.28±6.75 0.467
Activated partial thromboplastin time (s) 44.47±16.69 55.09±68.36 0.224
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modified, if needed, to obtain circuit ionized calcium in the
range 0.25–0.50 mmol/l (post-filter sample). To assess the
dosage of citrate in millimoles per hour delivered to the
patient, we calculated the estimated citrate load. The post-
dilution bicarbonate solution rate was adjusted to obtain a total
dialysis dose of >35 ml/kg/h. Calcium glubionate and calcium
gluconate (10 and 5 % solution, respectively, in children
weighing <10 kg) were infused in the separate central catheter
if a double-lumen catheter was used or in a venous single
catheter. Calcium compensation was defined as a percentage
of supplemented calcium solution when compared to calcium
loss with dialysate, and it was set to the machine according to
systemic calcium. Calcium solution flow was calculated au-
tomatically based on pre-dilution citrate load, dialysate flow
and type of calcium solution used. Systemic ionized calcium
was maintained in the normal range from 0.9 to 1.2 mmol/l.
In patients with HA-CRRT the conventional heparin pro-
tocol was applied as follows: mean initial bolus of
unfractionated heparin was in the range 20–30 IU/kg and
subsequent continuous infusion of heparin ranged from 10
to 20 IU/kg/h, adjusted to achieve the target activated partial
thromboplastin time (APTT) ratio of approximately 1.5.
PrismaSol 2 (Gambro) was used as a dialysate and replace-
ment fluid. Blood flow rate (BFR) was determined as 2–
3.6 ml/kg/min and ranged from 16 to 24 ml/min. The recom-
mended minimum BFR for the smallest HF20 filter is 20 ml/
min. In the children included in our study, it was very difficult
due to small-sized catheters to obtain a higher BFR. Hypoten-
sion, which is one of the complications that can arise at the
time the patient is being connected to the hemodiafiltration
system, especially cardiac patients, was defined as a fall in the
mean blood pressure of >20 mmHg relative to baseline during
the first 60min after connection to the CRRTsystem. To avoid
hypotension, the circuits were primed with 5 % albumin
solution or with blood. Multiorgan dysfunction syndrome
(MODS) was defined as the presence of at least three failed
organs. Organ system failure was defined using the interna-
tional pediatric sepsis consensus conference definitions [10].
The presence of acute liver failure was defined as the abrupt
loss of liver function without pre-existing liver disease and by
determining laboratory liver function parameters [elevated
aspartate aminotransferase and coagulopathywith a prothrom-
bin time of ≥15 s or an international normalized ratio of ≥1.5].
Due to general anesthesia, the encephalopathy criterion was
not considered [11]. Electrolyte disturbance during CRRTwas
as categorized as follows: hypocalcemia (ionized systemic
calcium <0.9 mmol/l), hypercalcemia (ionized systemic calci-
um >1.2 mmol/l), hyponatremia (sodium <129 mmol/l),
hypernatremia (sodium >143 mmol/l), metabolic acidosis
(pH <7.35, HCO3 <22 mmol/l) and metabolic alkalosis
(pH>7.45 and HCO3>26 mmol/l). The risk of bleeding in
patients who had undergone cardiac surgery was assessed
based on blood transfusion rate (ml/kg/day).
Statistical analysis was performed using Statistica ver. 8
(StatSoft, Tulsa, OK). The data are reported as the mean±
standard deviation. Normally distributed continuous variables
were tested using the analysis of variance with Tukey post-hoc
test. In all other cases, non-parametric tests were applied using
the Mann–Whitney and Kruskal–Wallis tests. Circuit lifetime
was assessed using Kaplan–Meier survival analysis, and sur-
vival curve distribution was compared with the log rank
(Mantel–Cox) test. The level of significance was set at p <0.05.
Results
The mean time on RCA-CRRT and HA-CRRT was 148.73±
131.58 and 110.24±105.38 h, respectively. In total, 43 circuits
were used in RCA-CRRT, with a filter life of 58.04±51.18 h
(median 39.75 h, range 1–171.8 h, total 2,379.65 h); when
scheduled CRRT shutdowns were excluded, the mean filter
life was 65.31±53.90 (median 72.25) h. Only five circuits
(11.63 %) had to be shut down due to filter clotting. The most
common cause of circuit shutdown was associated with the
handling of system alarms (Table 2). At the time of initiating
RCA-CRRT the pre-dilution citrate load was always 3 mmol
per liter of blood flow using the Prismocitrate 18/0 solution. In
15 children initial calcium compensation was 100%; only in 1
case, due to elevated systemic calcium, was calcium concen-
tration reduced to 90 %. The initial parameters of both RCA-
CRRTand HA-CRRTare given in Table 3. Total dialysis dose
in all children achieved the recommended level, and the mean
value was 52.32±35.63 ml/kg/h. Target circuit and systemic
Ca++ were easily maintained and were 0.38±0.05 and 1.17±
0.17 mmol/l, respectively.
In HA-CRRT the mean circuit functional survival was
37.64±32.51 h (median 25 h, range 2.25–121 h, total 1,
398.33 h). The main cause of circuit shutdown was clotting
(34.15 %; see Table 2 for other causes). Analysis of the main
metabolic and electrolyte parameters throughout the first 4 days
of RCA-CRRT revealed a significant reduction of systemic
Table 2 Causes of stops in CRRT
Cause of CRRT circuit shutdown Number of circuits (%)
RCA-CRRT HA-CRRT
Diuresis 8 (18.60) 5 (12.19)
Alarm handling/technical issues 13 (30.23) 8 (19.51)
Medical procedures 6 (13.95) 5 (12.19)
Death 7 (16.28) 7 (17.07)
CC malfunction 4 (9.30) 2 (4.88)
Clotting 5 (11.63) 14 (34.15)
Total number of circuits 43 41
CC, Central catheter; CRRT, continuous renal replacement therapy;
RCA, regional citrate anticoagulation; HA, heparin anticoagulation
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sodium and potassium levels on days 2, 3 and 4 versus the
initial value (pre- CRRT; day 0) (Fig. 1). A similar trend was
observed in HA-CRRT, but the differences were not significant
(Fig. 1). Hyponatremiawasmore common in children receiving
RCA-CRRT than in those on HA-CRRT (18.75 vs. 0 %,
respectively); the same was true for hypokalemia (62.5 vs.
28.6 %, respectively) (Table 4). Episodic mild hypo- and hy-
percalcemia was more frequent in children on RCA-CRRT, but
it was immediately offset by calcium compensation and citrate
load. During consecutive days of RCA-CRRT there were no
significant differences between the systemic and circuit calcium
loads (Fig. 1). The characteristic trend of a reduction in
calcium compensation and an increase in pre-dilution
citrate load was observed. Calcium compensation was
significantly lower on day 4 and on the last day of the
therapy than on day 1. The differences in citrate load at
these times were not significant.
Mild metabolic acidosis occurred in sevent of 16 patients on
RCA-CRRT and was treated by infusing sodium bicarbonate
into the dialysate fluid (3.06±4.63mmol/l dialysate).Metabolic
alkalosis was observed only in four cases (Table 4).
The blood transfusion rate in children after cardiac surgery did
not differ between the two study groups. However, the activated
partial thromboplastin time (APTT) was similar in both groups
during consecutive days of CRRT, as was the platelet count,
although the mean values were higher in the RCA-CRRT group.
Circuit lifetime was significantly higher for the RCA-
CRRT system when compared to the HA-CRRT system (p =
0.030). While 41.86 % of the circuits used in RCA-CRRT
functioned for longer than 72 h, only 21.95 % of those used in
HA-CRRT did so. For each anticoagulation modality, the
Kaplan–Meier curves of circuit lifetime probability, derived
from our analysis of scheduled and unscheduled CRRT inter-
ruptions, are displayed in Fig. 2.
The cessation of RCA-CRRT was due to effective diuresis
in nine cases and due to death in seven cases (in HA-CRRT: 5
and 9 children, respectively). The deaths were related to severe
disease andMODS. The survival at discharge from the hospital
was 37.5 % in the children receiving RCA-CRRT and 14.3 %
in those receiving HA-CRRT. At the time of discharge renal
function was normal, and no patients required dialysis.
Discussion
Continuous renal replacement therapy is closely related to
the need for efficient anticoagulation. Citrate provides re-
gional anticoagulation that is essentially restricted to the
Table 3 Initial parameters of CRRT
Parameters RCA-CRRT HA-CRRT




Estimated citrate load (mmol/h) 4.05±2.30 –
Dialysis dose (ml/kg/h) 52.32±35.63 71.71±39.39
Calcium compensation (%) 99.38±2.42 –
Heparin dose (IU/kg/h) – 17±10
–, Data not available; CRRT, continuous renal replacement therapy;
RCA, regional citrate anticoagulation; HA, heparin anticoagulation
Data are presented as the mean ± SD
Fig. 1 Systemic sodium and
ionized calcium loads during





Significant reduction of systemic
sodium load on days 2, 3 and 4
versus the initial (pre-CRRT)
value (day 0). p values were as
follows: p2=0.023; p3=0.015;
p4=0.005
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extracorporeal circuit, where it acts by chelating ionized
calcium. Our experience and the results of our analysis show
that this method is of great value even in small children—
but it is not perfect.
First, a certain amount of citrate reaches the systemic circu-
lationwhere itsmetabolism predominantly occurs in the hepatic
citric acid cycle; consequently, clearance is almost independent
of renal function [12, 13]. The metabolism of one citrate
molecule releases three sodium bicarbonate molecules and
ionized calcium [3, 14]. Therefore, the excess citrate can cause
metabolic alkalosis, hypernatremia and hypercalcemia, any of
which typically occurs after 36 h of treatment [3, 5, 14].
The most dangerous complication of RCA is systemic hy-
pocalcemia, which may even be life-threatening, especially in
cardiac patients [3, 5, 14]. Our analysis of electrolyte distur-
bances revealed the occurrence of episodic hypocalcemia in
seven of our patients (43.75%) on RCA-CRRT; in comparison,
no patient onHA-CRRT developed hypocalcemia. However, in
patients on RCA-CRRT, the hypocalcemia was incidental and
reached a minimum value of 0.7 mmol/l in one case. The
solubilized (s) Ca++ was immediately corrected by calcium re-
infusion through a separate line, and no side effects in terms of
cardiac dysrhythmia related to hypocalcemia were observed.
Although 50 % of patients suffered from acute liver failure, no
patient developed persistent hypocalcemia, and none required
citrate reduction or early cessation of CRRT. The calcium ratio
was in all cases below 2.5. Among our patients, the incidental
cases of hypocalcemia probably resulted from the dialytic
removal of the newly formed calcium citrate and the use of
calcium-free dialysate, which is also considered by other au-
thors to be a cause of calcium disturbances [3, 5, 14]. Liver
failure does not appear to be a contraindication to RCA.
Schultheiß et al. also postulate that RCA would appear to be
feasible in patients with severely impaired liver function [15, 16].
Hypercalcemia occurred in 43.75 % of our patients during
RCA-CRRT, while in those on HA-CRRT it was more com-
mon and persistent (64.3 %). In RCA-CRRT the maximum
value of systemic Ca++ was 1.4 mmol/l, suggesting that the
hypercalcemiawas probably due to additional calcium infusion,
such as in the total parenteral nutrition (TPN). In our opinion, it
is extremely important to control the composition and the rate of
infusion of all extra fluids given to the patient. If TPN contains
calcium, both the calcium concentration and the rate of infusion
should be stable. In our pediatric patients on RCA-CRRT, TPN
Table 4 Adverse events among the pediatric patient cohort on RCA-
CRRT and HA-CRRT






Hypernatremia (>143.0 mmol/l) 3 (18.75) 2 (14.3)
Hyponatremia (<129.0 mmol/l) 3 (18.75) 0 (0)
Hyperkalemia (>5,8 mmol/l) 2 (12.5) 3 (21.4)
Hypokalemia (<3,6 mmol/l) 10 (62.5) 4 (28.6)
Hypercalcemia (>1.2 mmol/l) 7 (43.75) 9 (64.3)
Hypocalcemia (<0.9 mmol/l) 7 (43.75) 0 (0)
Metabolic acidosis (pH<7.35 and HCO3
<22 mmol/l)
7 (43.75) 6 (42.9)
Metabolic alkalosis (pH>7.45 and
HCO3>26 mmol/l)
4 (25) 2 (14.3)
RCA, regional citrate anticoagulation; CRRT, continuous renal
replacement therapy; HA, heparin anticoagulation
Fig. 2 Kaplan–Meier curves of
circuit lifetime probability
according to RCA- and HA-
CRRT. Causes of scheduled
CRRT shutdowns have been
censored. Survival curve
distribution is compared with the
log rank (Mantel–Cox) test (p =
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resulted in a significant reduction of calcium compensation on
day 4 and the last day of treatment versus day 1.
An excessive citrate load can cause metabolic alkalosis. To
avoid an excessive alkali load, the dialysate fluid contains a
normal bicarbonate concentration (22 mmol/l). The
hyperchloremic fluids used in this protocol also reduce alkalosis.
Therefore, metabolic alkalosis occurred relatively rarely: in only
four children on RCA-CRRTand two children on HA-CRRT. A
more common adverse event among our patient cohort was
metabolic acidosis, which occurred in children on RCA-CRRT
and on HA-CRRT. In RCA-CRRTmetabolic acidosis can result
mainly from the difficulty in citrate metabolism [3, 5]. However,
the high dialysate flow and increased bicarbonate loss with
effluent can also result inmetabolic acidosis. It has been reported
that citrate clearance is similar to that of urea and that the
metabolic acidosis could result from a too high dialysis dose
and loss of bicarbonate with the effluent [17]. Themean value of
the dialysis dose in our study was 52.32±35.63 ml/kg/h.
A very important electrolyte disturbance during citrate
anticoagulation is hyper- or hyponatremia. The commercially
available citrate solutions contain high concentrations of cit-
rate and sodium [3]. The Prismocitrate 18/0 used in this study
contained 18 mmol/l trisodium citrate solution, and citrate
metabolism resulted in three additional molecules of sodium.
However, hypernatremia is uncommon if a hypo- or
isonatremic dialysate is used [5]. Our results confirm this:
short-lasting hypernatremia occurred only in three patients,
usually during the first day of treatment, and was related to
elevated initial sodium levels. The characteristic trend towards
a reduced sodium concentration during consecutive days of
RCA-CRRTwas observed, with a significant reduction of the
systemic sodium concentration becoming apparent on days 2,
3 and 4 versus the initial value on CRRT initiation (day 0).
Although in routine clinical practice, the sodium balance is not
only dependent upon potential sodium gains from the citrate
solutions but also on the sodium content of other infusions,
feeding and sodium losses through urine and drains, our
results indicate a citrate anticoagulation-dependent reduction
of systemic sodium with a minimum value of 121 mmol/l [3].
The findings of our study show a significantly longer circuit
lifespan during RCA-CRRT relative to HA-CRRT that resulted
in fewer connection–disconnection procedures. This is the main
advantage of using RCA-CRRT as shown in our study. This
observation is consistent those of other authors, who reported
better filter survival in adults [4, 18–20]. A better circuit lifespan
minimizes treatment downtime and reduces the risk of ineffec-
tive therapy, blood loss and hemodynamic instability during
circuit exchange [21]. This is especially important in very small
children who have a low blood volume andwho are additionally
at a high risk of the bradykinin release phenomenon [22]. The
longer circuit lifetime found in this study enhances the known
advantages of using RCA-CRRT. We did not compare pre-
scribed versus delivered dose as a measure of efficiency of
anticoagulation. The delivered dose of dialysis is a final conse-
quence of different factors, such as actual blood flow,membrane
permeability, convection rate, among others, which are some-
times overlying, overlapping and indistinguishable.
The most common cause of circuit shutdown in RCA-
CRRT was associated with the handling of alarms, while in
HA-CRRT it was associated with clotting. Most of the prob-
lems in RCA-CRRTwere caused by technical issues, probably
due to the small size of the circuits, low blood flow and small
catheters. Prolonged circuit lifetime, without filter clotting in
any case, has also been reported to be a cause of circuit
shutdown in RCA-CRRT [4, 18, 19]. However, these studies
were conducted in adults, and the authors targeted a lower
post-filter Ca++ level (<0.4 mmol/l) than we did in our study.
Although we found the mean value of circuit Ca++ was 0.38±
0.05 mmol/l, the episodic measurements above 0.40 mmol/l
might be sufficient to start clotting. Opatrny et al. concluded
that the usually recommended circuit Ca++ levels do not
guarantee complete prevention of hemostasis activation [23].
In another study, the post-filter Ca++ level reliably predicted
an activated coagulation time of >120 s, which was also
affected by citrate when the Ca++ targeted level was
≤0.30 mmol/l [24]. Therefore, in our opinion, a target level
of <0.40 mmol/l circuit Ca++ might better prevent clotting,
especially when small circuits with a low blood flow are used.
There were no significant differences in platelet count and
blood transfusion rate between patients on RCA- and HA-
CRRT. However, the APTT level was similar in both groups
during consecutive days of CRRT, and critically ill children
with a risk of clotting received systemic heparin. However, in
those patients on HA-CRRT, especially in cardiac patients, the
dosage of heparin was relatively low to reduce the risk of
bleeding, and the mean APTT level was 53±12 s. To assess
the effect of citrate on the risk of bleeding, further studies with
a larger and homogeneous group of patients are needed.
In summary, the critically ill childrenwith a low bodyweight
in our study, the RCA protocol adopted in our study appears to
be safe and easy to used. RCAwas more effective in preventing
circuit clotting when compared to heparin anticoagulation. The
metabolic and electrolyte complications were relatively low and
simple to correct even in patients with liver failure. We recom-
mend a target circuit Ca++ concentration of between 0.3 and
0.4 mmol/l as sufficient to prevent clotting.
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